KALA BIO Completes Enrollment in CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect

KALA BIO announced the completion of patient enrollment in the CHASE Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secreto...
Home/KnloSights/Clinical Trial Updates/KALA BIO Completes Enrollment in CHASE Trial for KPI-012 in Persistent Corneal Epithelial Defect